SCHEMBL1633264

SCHEMBL1633264

CC(=O)Nc1ncc2cccc(OC3CCN(C(C)C)CC3)c2n1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.56
JAK1 P23458 2/20 0.56
TYK2 P29597 2/20 0.56
JAK3 P52333 2/20 0.56
MCHR1 Q99705 2/20 0.46
TNIK Q9UKE5 1/20 0.42
HRH3 Q9Y5N1 5/20 0.41
HTR1A P08908 1/20 0.41
HTR1D P28221 1/20 0.41
HTR1B P28222 1/20 0.41
HTR1F P30939 1/20 0.41
ADORA2A P29274 1/20 0.40
SLC5A7 Q9GZV3 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
PARP1 P09874 2/20 0.39
PARP2 Q9UGN5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1632641 0.91 JAK2 (0.60) JAK2JAK1TYK2JAK3MCHR1
SCHEMBL1633776 0.89 JAK2 (0.59) JAK2JAK1TYK2JAK3MCHR1
SCHEMBL1633914 0.88 JAK2 (0.51) JAK2JAK1TYK2JAK3MCHR1
SCHEMBL13498310 0.85 JAK2 (0.51) JAK2JAK1TYK2JAK3MCHR1
SCHEMBL1634187 0.82 JAK2 (0.57) JAK2JAK1TYK2JAK3MCHR1
SCHEMBL12724803 0.82 JAK1 (0.57) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1632367 0.82 JAK2 (0.55) JAK2JAK1TYK2JAK3MCHR1
SCHEMBL1631106 0.82 JAK2 (0.57) JAK2JAK1TYK2JAK3TNIK
SCHEMBL1634280 0.82 MCHR1 (0.48) JAK2JAK1TYK2JAK3MCHR1
SCHEMBL1632408 0.81 JAK2 (0.56) JAK2JAK1TYK2JAK3TNIK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed